BRONITIN MIST (epinephrine bitartrate) by Pfizer is 12. Approved for regional anesthesia, analgesia for surgery, dental and 4 more indications. First approved in 1967.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
BRONITIN MIST is an inhaled epinephrine bitartrate aerosol approved in 1967 for emergency bronchospasm relief and anaphylaxis. It acts as a rapid-onset sympathomimetic agonist that promotes bronchodilation and peripheral vasoconstriction. The product treats acute respiratory distress in asthma, chronic obstructive pulmonary disease, and allergic reactions requiring immediate intervention.
Product approaching loss of exclusivity with moderate competitive pressure (30% intensity); brand team likely focused on life-cycle management and cost containment rather than growth initiatives.
12.1 Mechanism of Action Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the…
Worked on BRONITIN MIST at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on BRONITIN MIST offers limited career acceleration given its LOE-approaching status and zero linked job openings. Roles are primarily defensive, focused on maintaining market share, managing generic erosion, and optimizing profitability rather than driving innovation or revenue growth.